Drugs / Immune Killer Cells
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03515252 | Apr 2005 → Nov 2006 | hepatocellular carcinoma, non-small cell lung carcinoma | Ivy Life Sciences, Co., Ltd | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT03499834 | Dec 2017 → Feb 2020 | non-small cell lung carcinoma | Ivy Life Sciences, Co., Ltd | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Immune Killer Cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03499834 ↗ |
| Known as | IKC | “This study aimed to evaluate the efficacy and safety of Immune killer cells (IKC) in patients with stage IV NSCLC after the failure of prior chemotherapy.” PMID 39169058 ↗ Aug 20241“These immune cells are then proliferated over a two week period and used to produce our patented product IKC (Immune Killer Cells).” NCT03515252 ↗ |
| Modality | Cell therapy | “These immune cells are then proliferated over a two week period and used to produce our patented product IKC (Immune Killer Cells).” NCT03515252 ↗ |
| Route | Intravenous | “Intravenous Injection (I.V.)” NCT03499834 ↗ |